Kronos Bio, Inc. Banner Image

Kronos Bio, Inc.

  • Ticker KRON
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Kronos Bio, Inc. Logo Image
  • 51-200 Employees
  • Based in San Mateo, California
Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer. The company is developing the CDK9 inhibitor KB-0742 as a treatment for MYC-amplified solid tumors and other transcriptionally addicted solid tumors and lanraplenib, a next-generation SYK inhibitor, for patients with FLT3-mutated acute myeloid leukemiaMore. The company’s scientific focus is on developing medicines that target the deregulated transcription that is the hallmark of cancer and other serious diseases.
Kronos Bio, Inc.

Most Recent Annual Report

Kronos Bio, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Kronos Bio, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!